Overview

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

Status:
Enrolling by invitation

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.

Phase:

Phase 3

Details

Lead Sponsor:

BeiGene

Treatments:

Zanubrutinib